Recent News
In 2012, five years before he became the CSO of Bristol-Myers Squibb, Thomas Lynch began hearing from a Yale […] Read More...
Watch the Video to Learn More
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates against a range of hematological and solid tumors
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates against a range of hematological and solid tumors
Our Technologies
News
Returning guest Dr. Doug Manion’s current work developing cancer therapeutics has been uniquely informed by his connections to family and […] Read More
NEW HAVEN, Conn., Nov. 6, 2019 /PRNewswire/ — Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to […] Read More
NEW HAVEN, Conn., Nov. 4, 2019 /PRNewswire/ — Kleo Pharmaceuticals, Inc., a unique immuno-oncology company developing next-generation synthetic bispecific compounds designed to emulate […] Read More
Events
